The strong early efficacy data is a positive catalyst, but the small sample and need for FDA review to complete enrollment warrant caution. Monitor for completion of the 10-patient pilot and any regulatory updates; the next major catalyst is the interim safety analysis and full enrollment milestone.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 11 $1.02entry
- T+1 · 6mo ago 0.00%α +0.14% · $1.02
- T+5 · 6mo ago 0.00%α +0.09% · $1.02
- T+20 · 5mo ago 0.00%α +0.30% · $1.02
- T+60 · 3mo ago +230.39%α +226.00% · $3.37
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alpha Tau presented interim data from its REGAIN trial of Alpha DaRT for recurrent glioblastoma (GBM). Of the first three patients treated, two achieved complete responses and one stable disease with a 30% tumor reduction, with no unanticipated side effects. This is a strong early efficacy signal in a difficult-to-treat indication, though the sample is small and further enrollment and FDA review are pending.
Key Facts
- 3 patients treated in REGAIN trial for recurrent GBM
- 2 complete responses and 1 stable disease (30% size reduction) as of May 3, 2026
- No unanticipated side effects; grade 2-3 seizures occurred in 2 patients but resolved to baseline
- Plan to enroll 10 patients total pending FDA interim safety review
- Alpha DaRT uses diffusing alpha-emitters radiotherapy delivered via stereotactic implantation
Financial Impact
Pre-revenue company; no financial data provided
Risk Factors
- Small sample size (n=3) limits statistical reliability
- Two patients experienced grade 2-3 seizures, though manageable
- Regulatory and clinical risks: FDA may require additional data before allowing full enrollment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-054252 |
| Document: ea0290058-6k_alpha.htm | 0001213900-26-054252 |
| Document: 0001213900-26-054252-index-headers.html | 0001213900-26-054252 |
| Document: 0001213900-26-054252-index.html | 0001213900-26-054252 |
| Document: 0001213900-26-054252.txt | 0001213900-26-054252 |
Track record
14 reports on DRTSW
8 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +292.16% at T+60 after the Jun 3, 2026 report. 8 of 8 went positive at some point.
Filters
- Jun 3, 202623w ago 6-K Bullish 7/10 Entry $1.02 to $4.00 ▲ +292.16% +289.66% vs SPY
- Jun 1, 202624w ago 6-K Bullish 7/10 Entry $1.02 to $3.89 ▲ +281.37% +280.14% vs SPY
- May 18, 202626w ago 6-K Neutral 5/10 Entry $1.02 to $3.89 ▲ +281.37% +275.08% vs SPY
- May 11, 202627w ago 6-K Bullish 7/10 Viewing Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
- May 11, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
- May 8, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
- May 8, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
- May 7, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.58 ▲ +152.94% +149.11% vs SPY
- May 5, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.70 ▲ +164.71% +161.97% vs SPY
- May 4, 202628w ago 6-K Bullish 7/10 Entry $1.02 to $2.29 ▲ +124.51% +122.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers